Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.59 |
| ▸ | SPHK1 | Q9NYA1 | 8/20 | 0.57 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17141385 | 1.00 | GBA1 (0.59) | GBA1SPHK1SPHK2SIGMAR1 | |
| SCHEMBL312540 | 0.89 | SPHK1 (0.69) | SPHK1SPHK2 | |
| SCHEMBL4926619 | 0.89 | SPHK1 (0.69) | SPHK1SPHK2 | |
| SCHEMBL2169692 | 0.89 | SPHK1 (0.69) | SPHK1SPHK2 | |
| SCHEMBL2419294 | 0.89 | SIGMAR1 (0.60) | SPHK1SPHK2SIGMAR1 | |
| SCHEMBL1257009 | 0.88 | SPHK1 (0.64) | GBA1SPHK1SPHK2 | |
| SCHEMBL1051602 | 0.88 | SPHK1 (0.64) | GBA1SPHK1SPHK2 | |
| SCHEMBL6342866 | 0.88 | SPHK1 (0.64) | GBA1SPHK1SPHK2 | |
| SCHEMBL11990378 | 0.86 | SIGMAR1 (0.61) | GBA1SIGMAR1 | |
| SCHEMBL2921412 | 0.85 | GBA1 (0.56) | GBA1SPHK1SPHK2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113365995-B | Immunomodulators, compositions and methods thereof | 贝达药业股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-3908283-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| WO-2020146613-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146613-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| US-9375423-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-20140051702-A1 | Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2012125518-A1 | SALT FORMS OF 3 - CYCLOPROPYLCARBONYL - 3, 6 - DIAZABICYCLO [3.1.1] HEPTANE | TARGACEPT, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | Libertas Bio, Inc. | 2012-08-23 | — | — | US | disclosed |
| EP-1242370-A1 | SYNTHESIS OF CHIRAL 2-AZETIDINEMETHANOL COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-09-25 | — | — | EP | disclosed |
| EP-1242370-A1 | SYNTHESIS OF CHIRAL 2-AZETIDINEMETHANOL COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001046135-A1 | SYNTHESIS OF CHIRAL 2-AZETIDINEMETHANOL COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001046135-A1 | SYNTHESIS OF CHIRAL 2-AZETIDINEMETHANOL COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-06-28 | — | — | WO | disclosed |
| US-6124474-A | Synthesis of chiral 2-azetidinemethanol compounds | ABBOTT LABORATORIES (US) | 2000-09-26 | — | — | US | disclosed |
| US-6124474-A | Synthesis of chiral 2-azetidinemethanol compounds | ABBOTT LABORATORIES (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0165636-A1 | Process for preparing azetidine derivatives and intermediates therein | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1985-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | TRPA1, TRPV1, TRPV2 | GBA1 2334/4885SPHK1 1085/4885SPHK2 1481/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | GBA1 2271/4885SPHK1 2769/4885SPHK2 2756/4885 |
| US-20140051702-A1 | Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis | IDO1, IDO2, SLC1A2 | GBA1 3145/4885SPHK1 3757/4885SPHK2 2967/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | GBA1 2271/4885SPHK1 2769/4885SPHK2 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.